SCHEMBL3347232

SCHEMBL3347232

CCCNC(=O)c1cc(C(N)=O)cc(-c2nccs2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.44
CHEK2 O96017 1/20 0.43
F2 P00734 1/20 0.40
F10 P00742 1/20 0.40
PLG P00747 1/20 0.40
F7 P08709 1/20 0.40
F3 P13726 1/20 0.40
LRRK2 Q5S007 1/20 0.40
HDAC3 O15379 3/20 0.39
HDAC1 Q13547 3/20 0.39
HDAC6 Q9UBN7 3/20 0.39
HPGD P15428 2/20 0.39
HDAC2 Q92769 2/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
SIRT1 Q96EB6 1/20 0.39
SIRT3 Q9NTG7 1/20 0.39
RIPK1 Q13546 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC10 Q969S8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3350405 0.83 CHEK2 (0.47) SMN1; SMN2CHEK2F2F10PLG
SCHEMBL6650208 0.81 NAAA (0.46) SMN1; SMN2F2F10PLGF7
SCHEMBL6889422 0.80 L3MBTL1 (0.53) SMN1; SMN2HPGDALDH1A1L3MBTL1
SCHEMBL3350750 0.78 CHEK2 (0.43) CHEK2F2LRRK2HPGDHDAC2
Hydrochloric Acid SCHEMBL3351582 0.77 CHEK2 (0.42) CHEK2F2LRRK2HPGDHDAC2
Hydrochloric Acid SCHEMBL3349089 0.77 CHEK2 (0.42) CHEK2F2LRRK2HPGDHDAC2
SCHEMBL6685843 0.74 CHEK2 (0.39) SMN1; SMN2CHEK2F2F10PLG
SCHEMBL20991495 0.74 L3MBTL1 (0.47) SMN1; SMN2HPGDALDH1A1L3MBTL1
SCHEMBL18459982 0.74 L3MBTL1 (0.47) SMN1; SMN2HPGDALDH1A1L3MBTL1
Hydrochloric Acid SCHEMBL6686950 0.74 CHEK2 (0.38) SMN1; SMN2CHEK2HDAC3HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP SMN1; SMN2 1298/4885CHEK2 3158/4885F2 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.